{"hits":[{"_index":"eclaire","_id":"2024-500014-26-99","_score":null,"_source":{"phase":{"coding":[{"code":"phase-3","system":"http://terminology.hl7.org/CodeSystem/research-study-phase","display":"Phase 3","version":"1.0.0"}],"text":"Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug."},"identifier":[{"use":"official","assigner":{"reference":"Organization/ctis","display":"Reference to primary assigner","type":"Organization"},"value":"2024-500014-26-99"}],"extension":[{"valueString":"Diseases [C] - Neoplasms [C04]","url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-therapeutic-area"},{"valuePeriod":{"start":"2022-06-30T00:00:00.000Z"},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-period"},{"extension":[{"valueString":"F. Hoffmann-La Roche AG","url":"name"},{"valueCodeableConcept":{"coding":[{"code":"lead-sponsor","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-study-party-role-code-system","display":"lead-sponsor","version":"0.3.0"}]},"url":"role"},{"valueReference":{"reference":"Organization/2024-500014-26-99-primary-sponsor","display":"Reference to primary sponsor","type":"Organization"},"url":"party"}],"url":"https://hl7.org/fhir/5.0/StructureDefinition/extension-ResearchStudy.associatedParty"},{"valueCodeableConcept":{"coding":[{"code":"upcoming","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-status-recruitment-code-system","display":"A venir / Upcoming","version":"0.3.1"}]},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-recruitment-status"}],"originalContentsToEnhance":{"meddraCodes":["10070575","10065430"]},"title":"A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER","enrollment":[{"reference":"Group/2024-500014-26-99-enrollment-group","display":"Reference to group detailing study characteristics","type":"Group"}],"condition":[{"id":"disease-condition-2024-500014-26-99","text":"Locally-Advanced or Metastatic breast cancer (MBC)"},{"coding":[{"code":"10070575","system":"https://www.meddra.org","display":"Cancer du sein à récepteurs aux oestrogènes positifs","version":"3.0.0"}],"id":"meddra-condition-2024-500014-26-99-10070575"},{"coding":[{"code":"10065430","system":"https://www.meddra.org","display":"Cancer du sein HER2 positif","version":"3.0.0"}],"id":"meddra-condition-2024-500014-26-99-10065430"}],"site":[{"reference":"Location/2024-500014-26-99-0-site","display":"Reference to site","type":"Location"}],"meta":{"lastUpdated":"2024-01-06T00:00:00.000Z","profile":["https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-researchstudy"]},"contact":[{"extension":[{"valueHumanName":{"given":["Head of EU"],"use":"official","family":"Trial Information Support Line-TISL, Switzerland"},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-name"},{"valueAddress":{"country":"Basel Town","city":"Switzerland","line":["Grenzacherstrasse 124"],"use":"work","postalCode":"4058","type":"physical"},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-address"},{"valueCodeableConcept":{"coding":[{"code":"SCI","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-type-contact-code-system","display":"Scientifique / Scientific","version":"0.3.0"}]},"url":"https://interop.esante.gouv.fr/ig/fhir/eclaire/StructureDefinition/eclaire-contact-type"}],"name":"F. Hoffmann-La Roche AG","telecom":[{"system":"phone","use":"work","value":"0041616881111"},{"system":"email","use":"work","value":"global.rochegenentechtrials@roche.com"}]}],"location":[{"coding":[{"code":"BE","system":"urn:iso:std:iso:3166","display":"Belgium","version":"4.0.1"}]},{"coding":[{"code":"DE","system":"urn:iso:std:iso:3166","display":"Germany","version":"4.0.1"}]},{"coding":[{"code":"ES","system":"urn:iso:std:iso:3166","display":"Spain","version":"4.0.1"}]},{"coding":[{"code":"FR","system":"urn:iso:std:iso:3166","display":"France","version":"4.0.1"}]},{"coding":[{"code":"HU","system":"urn:iso:std:iso:3166","display":"Hungary","version":"4.0.1"}]},{"coding":[{"code":"IT","system":"urn:iso:std:iso:3166","display":"Italy","version":"4.0.1"}]},{"coding":[{"code":"PL","system":"urn:iso:std:iso:3166","display":"Poland","version":"4.0.1"}]},{"coding":[{"code":"PT","system":"urn:iso:std:iso:3166","display":"Portugal","version":"4.0.1"}]}],"id":"2024-500014-26-99","text":{"div":"<div xmlns=\"http://www.w3.org/1999/xhtml\"><h2>Données reçues avant modélisation FHIR</h2><ul><li> reglementation_code: REG536 </li><li> precision_reglementation: un essai clinique (CTIS) </li><li> etat: EN_COURS </li><li> organisme_nom: F. Hoffmann-La Roche AG </li><li> organisme_adresse: Grenzacherstrasse 124 </li><li> organisme_code_postal: 4058 </li><li> organisme_pays: Switzerland </li><li> organisme_ville: Basel Town </li><li> contact_nom: Trial Information Support Line-TISL, Switzerland </li><li> contact_prenom: Head of EU </li><li> contact_telephone: 0041616881111 </li><li> contact_courriel: global.rochegenentechtrials@roche.com </li><li> sites: Organisme: Donnée non disponible - Adresse: Avenue Eugene Avinee - Ville: Lille - Titre: Dr. - Nom: Aumar - Prenom: Madeleine - Service: Gastroenterology Hepatology and Nutrition Unit Paediatric clinic, Child Unit - Code_postale: 59350 - courriel: test@sante.gouv - telephone: 0168496726 </li><li> numero_primaire: 2024-500014-26-99 </li><li> titre: A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER </li><li> phase_recherche: Phase III </li><li> domaine_therapeutique: Diseases [C] - Neoplasms [C04] </li><li> pathologies_maladies_rares: Locally-Advanced or Metastatic breast cancer (MBC) </li><li> informations_meddra: 10070575,10065430 </li><li> taille_etude: 21 </li><li> tranches_age: 65+ years,18-64 years </li><li> sexe: Male,Female </li><li> groupes_sujet: Données non disponible </li><li> population_recrutement: Women of child bearing potential not using contraception,Women of child bearing potential using contraception </li><li> date_debut_recrutement: 2022-06-30T00:00:00.000Z </li><li> historique: 2024-01-06: En cours </li><li> dates_avis_favorable_ms_mns: 22.00800.000094-SM-1:2022-11-07, 22.00800.000094-SM-2:2024-01-06 </li><li> pays_concernes: BE,DE,ES,FR,HU,IT,PL,PT </li><li> date_theorique_maximale_autorisation_cpp: 2023-03-15 </li><li> contact_public: Nom: null - Prenom: null Courriel: null Tel: null </li><li> criteres_eligibilite: Titre: null - Type: null,Titre: TEST INCLUSION - Type: INCLUSION,Titre: TEST EXCLUSION - Type: EXCLUSION </li><li> criteres_jugement: Titre: null - Type: null,Titre: TEST PRINCIPAL - Type: PRINCIPAL,Titre: TEST SECONDAIRE - Type: SECONDAIRE </li><li> objectifs: null </li><li> resume: null </li><li> statut_recrutement: Recrutement en attente </li><li> date_fin_recrutement: null </li></ul></div>","status":"extensions"},"category":[{"coding":[{"code":"REG536","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-regulation-code-code-system","display":"REG536 (CTIS)","version":"0.3.0"}]},{"coding":[{"code":"study-ctis","system":"https://interop.esante.gouv.fr/ig/fhir/eclaire/CodeSystem/eclaire-reglementation-precision-code-system","display":"un essai clinique (CTIS)","version":"0.3.0"}]}],"translatedContent":{"judgmentCriteria":["[Traduction locale] TEST PRINCIPAL","[Traduction locale] TEST SECONDAIRE"],"diseaseCondition":"[Traduction locale] Locally-Advanced or Metastatic breast cancer (MBC)","eligibilityCriteria":["[Traduction locale] TEST INCLUSION","[Traduction locale] TEST EXCLUSION"],"therapeuticArea":"[Traduction locale] Diseases [C] - Neoplasms [C04]","title":"[Traduction locale] A PHASE III, RANDOMIZED, OPEN-LABEL STUDY EVALUATING THE EFFICACY AND SAFETY OF GIREDESTRANT IN COMBINATION WITH PHESGO VERSUS PHESGO AFTER INDUCTION THERAPY WITH PHESGO+TAXANE IN PATIENTS WITH PREVIOUSLY UNTREATED HER2-POSITIVE, ESTROGEN RECEPTOR-POSITIVE LOCALLY-ADVANCED OR METASTATIC BREAST CANCER"},"resourceType":"ResearchStudy","status":"active"},"sort":[1704499200000,"2024-500014-26-99","active"]}],"total":1}